Keros Therapeutics (KROS) Receivables - Other (2019 - 2021)
Keros Therapeutics (KROS) reported Receivables - Other of $100000.0 for Q2 2021, down 87.58% quarter-over-quarter from $805000.0 in Q1 2020.
Keros Therapeutics (KROS) Receivables - Other (2019 - 2021) Analysis & Trends
Keros Therapeutics has reported Receivables - Other for 3 years, with the latest figure at $100000.0 in Q2 2021.
- For the quarter ending Q2 2021, Receivables - Other changed N/A year-over-year to $100000.0; the trailing twelve-month figure through Jun 2021 stood at $100000.0 (changed N/A YoY), and the FY2019 full-year result was $900000.0, changed N/A from the prior year.
- Receivables - Other for Q2 2021 stood at $100000.0, down from $805000.0 in the prior quarter.
- The five-year high for Receivables - Other was $900000.0 in Q4 2019, with the low at $100000.0 in Q2 2021.
- Historically, Receivables - Other has averaged $601666.7 across 3 years, with a median of $805000.0 in 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Keros Therapeutics | 399.01 Mn | 111.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Mar 31, 2020 | 805,000.00 |
| Mar 31, 2020 | 805,000.00 |
| Dec 31, 2019 | 900,000.00 |
| Dec 31, 2019 | 900,000.00 |